These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27621651)

  • 1. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
    Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
    Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Photoinduced Biological Properties of Verteporfin.
    Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
    Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.
    Wei C; Li X
    Front Pharmacol; 2020; 11():557429. PubMed ID: 33178014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
    Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
    Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
    Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
    Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    Wei C; Li X
    BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation.
    Lin L; Zheng Y; Li Q; Sun Y; Huang Y; Liang L; Xu L; Zhao YE
    Exp Eye Res; 2024 Jan; 238():109747. PubMed ID: 38072353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation.
    Chen M; Zhong L; Yao SF; Zhao Y; Liu L; Li LW; Xu T; Gan LG; Xiao CL; Shan ZL; Liu BZ
    Int J Med Sci; 2017; 14(10):1031-1039. PubMed ID: 28924376
    [No Abstract]   [Full Text] [Related]  

  • 12. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma.
    Lui JW; Xiao S; Ogomori K; Hammarstedt JE; Little EC; Lang D
    J Cancer; 2019; 10(1):1-10. PubMed ID: 30662519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer.
    Huang C; Chen Z; Yang C; Chen L; Lai C; Zhang Y; Yuan W; Jeong JH
    J Cancer; 2020; 11(18):5432-5439. PubMed ID: 32742490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.
    Li Y; Yang S; Yang S
    Cells; 2022 Apr; 11(8):. PubMed ID: 35456040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the hippo-YAP pathway by cyclic stretch in rat type 2 alveolar epithelial cells-a proof-of-concept study.
    Ran X; Müller S; Brunssen C; Huhle R; Scharffenberg M; Schnabel C; Koch T; Gama de Abreu M; Morawietz H; Ferreira JMC; Wittenstein J
    Front Physiol; 2023; 14():1253810. PubMed ID: 37877098
    [No Abstract]   [Full Text] [Related]  

  • 16. YAP Inhibition by Verteporfin Causes Downregulation of Desmosomal Genes and Proteins Leading to the Disintegration of Intercellular Junctions.
    Huang Y; Ahmad US; Rehman A; Uttagomol J; Wan H
    Life (Basel); 2022 May; 12(6):. PubMed ID: 35743822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth.
    Morice S; Mullard M; Brion R; Dupuy M; Renault S; Tesfaye R; Brounais-Le Royer B; Ory B; Redini F; Verrecchia F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin as a Medical Treatment in Peyronie's Disease.
    Mohede DCJ; de Jong IJ; Bank RA; van Driel MF
    Sex Med; 2018 Dec; 6(4):302-308. PubMed ID: 30274909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin Suppresses YAP-Induced Glycolysis in Breast Cancer Cells.
    Chen H; Zhang LF; Miao Y; Xi Y; Li X; Liu MF; Zhang M; Li B
    J Invest Surg; 2023 Dec; 36(1):2266732. PubMed ID: 37828756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm.
    Wang C; Zhu X; Feng W; Yu Y; Jeong K; Guo W; Lu Y; Mills GB
    Am J Cancer Res; 2016; 6(1):27-37. PubMed ID: 27073720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.